
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals is expecting a meaningful increase in quarterly revenue in the second half of 2026 driven by the 50% expansion in their sales force, and their overall earnings and non-GAAP EPS were ahead of expectations in 2Q 2026. Despite moderating guidance for their Rare Disease segment, we remain bullish on the company's long-term prospects given the potential for Cortrophin sales to exceed $800M annually by 2029 and a strong generics business.
Bears say
ANI Pharmaceuticals is currently facing several fundamental challenges that may negatively impact their financial performance in the long term. These challenges include the potential for unforeseen clinical, regulatory, manufacturing, or commercial setbacks or delays, especially with their Purified Cortrophin Gel and ILUVIEN products, as well as continued challenges with the Alimera integration and executing attractive deals in the future. Additionally, the company may also face worsening pricing and competitive pressures in the generics industry.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares